Literature DB >> 19903734

Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.

Junchao Tong1, Henry Wong, Mark Guttman, Lee C Ang, Lysia S Forno, Mitsunobu Shimadzu, Ali H Rajput, Manfred D Muenter, Stephen J Kish, Oleh Hornykiewicz, Yoshiaki Furukawa.   

Abstract

Alpha-synuclein is a major component of Lewy bodies and glial cytoplasmic inclusions, pathological hallmarks of idiopathic Parkinson's disease and multiple system atrophy, and it is assumed to be aetiologically involved in these conditions. However, the quantitative status of brain alpha-synuclein in different Parkinsonian disorders is still unresolved and it is uncertain whether alpha-synuclein accumulation is restricted to regions of pathology. We compared membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein, both the full-length 17 kDa and high molecular weight species, by western blotting in autopsied brain of patients with Parkinson's disease (brainstem-predominant Lewy body disease: n = 9), multiple system atrophy (n = 11), progressive supranuclear palsy (n = 16), and of normal controls (n = 13). Brain of a patient with familial Parkinsonism-dementia due to alpha-synuclein locus triplication (as positive control) showed increased membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein levels with abundant high molecular weight immunoreactivity. In multiple system atrophy, a massive increase in 17 kDa membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein was observed in highly pathologically affected regions, including putamen (+1760%, range +625-2900%), substantia nigra [+1000% (+356-1850%)], and white matter of internal capsule [+2210% (+430-6830%)] together with numerous high molecular weight species. Levels of 17 kDa membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein were only modestly increased in less affected areas (cerebellar cortex, +95%; caudate, +30%; with both also showing numerous high molecular weight species) and were generally normal in cerebral cortices. In both Parkinson's disease and progressive supranuclear palsy, membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein levels were normal in putamen and frontal cortex whereas a trend was observed for variably increased 17 kDa membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein concentrations [+184% (-60% to +618%)] with additional high molecular weight species in Parkinson's disease substantia nigra. No obvious correlation was observed between nigral membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein accumulation and Lewy body density in Parkinson's disease. Two progressive supranuclear palsy cases had membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein accumulation in substantia nigra similar to multiple system atrophy. Several Parkinson's disease patients had very modest high molecular weight membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein accumulation in putamen. Levels of 17-kDa membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein were generally positively correlated with those of high molecular weight membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein and there was a trend for a positive correlation between striatal dopamine loss and 17-kDa membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein concentrations in multiple system atrophy. Brain membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein accumulations in Parkinson's disease and multiple system atrophy are regionally specific, suggesting that these sporadic alpha-synucleinopathies, unlike familial Parkinsonism-dementia, are not associated with a simple global over-expression of the protein. Despite a similar extent of dopamine depletion, the magnitude of brain membrane-associated, sodium dodecyl sulfate-soluble alpha-synuclein changes is disease specific, with multiple system atrophy clearly having the most severe accumulation. Literature discrepancies on alpha-synuclein status in 'Parkinson's disease' might be explained by inclusion of cases not having classic brainstem-predominant Lewy body disease and by variable alpha-synuclein accumulation within this diagnostic classification.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903734     DOI: 10.1093/brain/awp282

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  78 in total

Review 1.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

2.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

3.  Concentration, distribution, and influence of aging on the 18 kDa translocator protein in human brain: Implications for brain imaging studies.

Authors:  Junchao Tong; Belinda Williams; Pablo M Rusjan; Romina Mizrahi; Jean-Jacques Lacapère; Tina McCluskey; Yoshiaki Furukawa; Mark Guttman; Lee-Cyn Ang; Isabelle Boileau; Jeffrey H Meyer; Stephen J Kish
Journal:  J Cereb Blood Flow Metab       Date:  2019-06-20       Impact factor: 6.200

4.  Neuronal to oligodendroglial α-synuclein redistribution in a double transgenic model of multiple system atrophy.

Authors:  Edward Rockenstein; Kiren Ubhi; Chandra Inglis; Michael Mante; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Neuroreport       Date:  2012-03-07       Impact factor: 1.837

5.  Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.

Authors:  Junchao Tong; Lee-Cyn Ang; Belinda Williams; Yoshiaki Furukawa; Paul Fitzmaurice; Mark Guttman; Isabelle Boileau; Oleh Hornykiewicz; Stephen J Kish
Journal:  Neurobiol Dis       Date:  2015-06-21       Impact factor: 5.996

6.  Identification of characteristic proteins at late-stage erythroid differentiation in vitro.

Authors:  Koji Funato; Takaaki Abe; Ryo Kurita; Yoshihisa Watanabe; Yukio Nakamura; Shigeki Miyata; Yusuke Furukawa; Masahiro Satake
Journal:  Hum Cell       Date:  2021-02-22       Impact factor: 4.174

7.  Spinal cord involvement in Lewy body-related α-synucleinopathies.

Authors:  Raffaele Nardone; Yvonne Höller; Francesco Brigo; Viviana Versace; Luca Sebastianelli; Cristina Florea; Kerstin Schwenker; Stefan Golaszewski; Leopold Saltuari; Eugen Trinka
Journal:  J Spinal Cord Med       Date:  2019-01-08       Impact factor: 1.985

Review 8.  Novel therapeutic approaches in multiple system atrophy.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Clin Auton Res       Date:  2014-06-14       Impact factor: 4.435

9.  Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.

Authors:  David S Goldstein; Patricia Sullivan; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi; Deborah C Mash
Journal:  Parkinsonism Relat Disord       Date:  2015-03-20       Impact factor: 4.891

Review 10.  Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.

Authors:  Xuling Li; Simon James; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-09-15       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.